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The aminoglycoside Geneticin (G418) is known to inhibit cell culture proliferation, via virus-specific mechanisms, of two differ-
ent virus genera from the family Flaviviridae. Here, we tried to determine whether Geneticin can selectively alter the switching of
the nucleotide 1 to 570 RNA region of hepatitis C virus (HCV) and, if so, whether this inhibits viral growth. Two structure-de-
pendent RNases known to specifically cleave HCV RNAwere tested in the presence or absence of the drug. One was the Syn-
echocystis sp. RNase P ribozyme, which cleaves the tRNA-like domain around the AUG start codon under high-salt buffer condi-
tions; the second was Escherichia coli RNase III, which recognizes a double-helical RNA switch element that changes the internal
ribosome entry site (IRES) from a closed (C) conformation to an open (O) one. While the drug did not affect RNase P activity, it
did inhibit RNase III in the micromolar range. Kinetic studies indicated that the drug favors the switch from the C to the O con-
formation of the IRES by stabilizing the distal double-stranded element and inhibiting further processing of the O form.We
demonstrate that, because the RNA in this region is highly conserved and essential for virus survival, Geneticin inhibits HCV Jc1
NS3 expression, the release of the viral genomic RNA, and the propagation of HCV in Huh 7.5 cells. Our study highlights the
crucial role of riboswitches in HCV replication and suggests the therapeutic potential of viral-RNA-targeted antivirals.
Chronic hepatitis C virus (HCV) infection is a progressive dis-ease affecting an estimated 185 million people worldwide (1).
Several treatments and combination therapies for chronic hepati-
tis C have gradually been replaced over the last 35 years. The initial
treatments, with low efficacy, high costs, and severe side effects,
have evolved into today’s modern therapies involving direct-act-
ing antiviral (DAA) inhibitors (1). The development of the viral
nonstructural protein 5B (NS5B) polymerase inhibitor known as
sofosbuvir represents an important advance in the fight against
HCV (2, 3). Using sofosbuvir in combination with ribavirin in
patients with genotype 3 infection, high rates of sustained viro-
logic response have been obtained, between 68% and 91% in the
presence or absence of cirrhosis, respectively (4). While this is a
very encouraging result, significant disadvantages still exist: cur-
rent antiviral treatment options are expensive (1), antiviral resis-
tance is likely to develop (5, 6), there is naturally occurring poly-
morphism (7, 8, 9), and efficacy is still limited in those patients in
whom infection has led to cirrhosis (4). Therefore, new categories
of drugs are needed to supplement or replace existing drug regi-
mens.
Geneticin (also called G418) is an aminoglycoside antibiotic
known to be effective against infection by members of the family
Flaviviridae: both bovine viral diarrhea virus (BVDV) (10), a
member of the genus Pestivirus, and dengue virus, a member of
the genus Flavivirus (11). The antiviral mechanism of the drug
against these viruses is unknown. However, the inability of Gene-
ticin to inhibit replication in yellow fever virus (YFV) in the same
cell where dengue virus is blocked (11) suggests that Geneticin
interacts directly with viral RNA. If Geneticin worked on the level
of general cellular translation, both viruses would be inhibited.
Furthermore, it is known that Geneticin specifically interacts with
certain tertiary RNA structures formed from asymmetrical inter-
nal loops involving noncanonical base pairs (12), as revealed by its
interaction with the A site on bacterial 16S rRNA (13, 14). This
ribosomalmotif, formedbetween complementary sequences 1404
to 1410 and 1490 to 1496, participates in an essential RNA switch
during translation,which is shunted by the drug, provoking loss of
translation fidelity (13). The crystal structure of Geneticin bound
to a model RNA fragment containing the A site has provided de-
tailed information about its interaction site. The main conclusion
was that, compared to other aminoglycosides, Geneticin offers the
ability to accommodate several point mutations associated with
resistance or phylogenetic variations (14).
Geneticin is the only cell-permeable aminoglycoside known to
date. It has been observed to be one of the least toxic aminoglyco-
sides in animalmodels, where the aminoglycosides tested, in order
of increasing toxicity, were as follows: kanamycin and amikacin
geneticin  neomycin, paromomycin, streptomycin, and tobra-
mycin  gentamicin  hygromycin B (15). The clinical use of
Geneticin as an antiparasitic agent has also been proposed (16),
and its administration has proven helpful in the treatment of ge-
netic disorders (17).
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The basis for evaluating such a compound in a highly variable
virus like HCV (18) resides in the concept that it may attack se-
quences in untranslated regions (UTR), such as the 5= or 3= ends,
which are far less variable, and that although these regions un-
dergo mutations, their functional structures should be more con-
served (19) and therefore susceptible to treatment.
The 5=UTR of HCV and the first third of its downstream core-
coding region, approximately nucleotides (nt) 1 to 600, is themost
highly conserved sequence among the different isolates (20, 21).
This sequence encodes a high variety of tertiary structures that
participate in several essential viral functions, such as initiating
translation in viral replication, balancing the proportion entering
into translation or replication, and stabilizing the viral genome
(22–28). Two of the main structures described along the HCV 5=
nt 1 to 570 sequence are of particular interest for the present work:
a tRNA-like domain (29–31) and a double-stranded RNA switch
structure (32, 33). These domains were primarily identified by the
use of structure-dependent RNases P and III, respectively.
RNase P is the tRNA precursor (pre-tRNA) processing enzyme
that cleaves mature tRNA (34) and structures that mimic tRNA
(35–42); these structures includeHCV-related animal pestiviruses
(43) and unrelated virus families (43–45). Both the RNase P pu-
rified from HeLa cells and the ribozyme moiety from the cyano-
bacterium Synechocystis sp. cleaveHCVRNAat a positionnear the
AUG start triplet (Fig. 1A) (29, 30).
RNase III is a specific double-stranded RNase (dsRNase) that
cleaves regions of 20 bp of RNA in double-stranded structures
and certain other specific regions with less perfect base pairings,
which invariably contain approximately two turns of essentially
regular dsRNA (46–48). Biologically, it participates in several
RNA-processing activities, such as the maturation of rRNA (48,
49). A well-studied example is the processing of the early mRNA
region, known as R1.1, of the T7 bacteriophage (50, 51). In addi-
tion to its primary cleavage activity, RNase III is also known to
present secondary cleavage activity (52). The phenomenon was
characterized as a set of specific cleavage reactions carried out by
the Escherichia coli RNase III enzyme that are favored at high en-
zyme/substrate ratios and/or higher concentrations of monova-
lent cations. They behave like primary cleavage reactions because
(i) they are effectively inhibited by dsRNA competitors but not by
largemolar excesses of single-strandedRNA (ssRNA) and (ii) they
are reproducible and specific, yielding the same chemical end
groups as those of primary cleavages (48, 52).
Several studies indicated that bases 428 to 442 within the HCV
coding region interact with the complementary 5= unstructured
sequence, bases 24 to 38, forming a long-range annealing (LRA)
motif (closed [C] conformation). Alternatively, the sequence of
the core-coding domain may self-fold in what is called stem-loop
VI, where bases 428 to 442 are paired with bases 495 to 508 (open
[O] conformation). The transition between two double-helical
elements has been characterized in the context of a conforma-
tional change of HCV RNA nt 1 to 570 (RNA1–570) and its dy-
namic in vitro modulation by the liver-specific microRNA. Both
dsRNA elements are cleaved by RNase III under secondary condi-
tions of cleavage (32, 33). First, starting in the C conformation,
both proximal and distal LRA chains are cleaved, providing P2P3
and P1P2, respectively. After these cleavages, P1P2 is further pro-
cessed to produce P1 plus P2, and P2P3 either produces P2 plus P3
or switches to spontaneously providing the O form, where stem-
loopVI is cleaved to produce a product called X.WhenHCVRNA
nt 1 to 570 is preincubated in the presence of microRNA-122
(miR-122) before cleavage, themicroRNA competes with the LRA
duplex to bind to HCV sequences between positions 1 and 40 and
makes the structure transition to the O form. This form cleaves to
produce a product that is longer than X, which was determined to
be P1-X, because cleavage at this site is inhibited by the presence of
annealed miR-122 (Fig. 1A). RNase III has also been found to
cleave BVDV and classical swine fever virus (CSFV) at sites sur-
rounding their respective internal ribosome entry sites (IRESs)
(unpublished data). Liver-specific miR-122 has an essential and
complex role in HCV biology (25, 26, 53–55).
The main objective of the present work was to discover
whether the compound Geneticin, known to bind and perturb
RNA structural switches and observed to inhibit the growth of
HCV-related virus genera that share common RNA structures in
similar regions, can also inhibit HCV. In contrast to work on
Flavivirus and Pestivirus, here, we started by investigating whether
Geneticin interfered with RNase III in vitro processing and subse-
quently demonstrated that it could block HCV infection in cell
cultures.
MATERIALS AND METHODS
Preparation of RNA substrates. The RNA transcripts used as substrates
in the human RNase III assays were derived from plasmid pN(1-4728)
Bluescript, which contains nt 1 to 4728 of hepatitis C virus cleaved with
BlpI and leaves nt 1 to 570 of the HCV genome under the T7 promoter.
Control reactions employed a synthetic DNA containing the sequence of
the naturally occurring precursor R1.1 from the T7 bacteriophage, also
under the T7 promoter. To obtain the radioactive substrates, 1 to 2 g of
DNA template was transcribed in vitro (1 h at 37°C) with [-32P]GTP,
followed by a 10-min treatment with RNase-free RQ1 (RNA-qualified)
RNase-free DNase I at 37°C and phenol extraction. We used CF11 (cellu-
lose fiber) chromatography to eliminate DNA fragments and nonincor-
porated nucleotides. The transcripts were then purified using gel electro-
phoresis under denaturing conditions on 4% polyacrylamide gels
containing 7 M urea. The bands were visualized by autoradiography, ex-
cised from the gel, and eluted in buffer (100mMTris-HCl, pH 7.5, and 10
mM EDTA, pH 7.5). The concentration of radioactive transcripts was
determined by calculating the amount of incorporated [-32P]GTP,
based on scintillation counting.
RNase P ribozyme cleavage. The RNase P ribozyme from strain
PCC6803 from Synechocystis species (56, 57) was prepared by in vitro
transcription as described previously (30). The salt and buffer conditions
used for experiments on HCV RNA cleavage were the same as those used
previously to detect cleavage onHCVRNA: 50mMTris-HCl, pH 7.5, 100
mMMgCl2, and 1 M KCl preincubated for 15 min at 37°C before adding
the labeled substrate (1.8 nM). The cleavage reaction was performed for
30 min.
RNase III cleavage. RNase III digestion was performed on renatured
HCV RNA under “secondary conditions of cleavage”: HCV and R1.1
RNA substrates (final concentration, 0.6 nM) were preheated at 90°C for
1 min before adding reaction buffer [10 mM HEPES-KOH, pH 7.5, 10
mM Mg(OAc)2 (magnesium acetate), and 100 mM NH4(OAc) (ammo-
nium acetate)] and then leaving it to cool to room temperature. In reac-
tions with Geneticin, the drug was added after the 1-hour-long RNA-
renaturing step. Cleavage reactions were performed at 0.001 and 0.005
U/ml of E. coli RNase III (Ambion) in the presence of 2 g of Saccharo-
myces cerevisiae tRNA and 20 U RNasin (Promega) and were carried out
for 1 h at 37°C in a volume of 10 l. These conditions were used in all of
the experiments. The cleavage products were separated on 4% and 10%
denaturing polyacrylamide gels for HCV or R1.1 RNA, respectively, and
visualized using autoradiography on RX film (Curix RP2 plus; Agfa).
Quantitative data regarding RNase III cleavage kinetics were obtained
using a phosphorimager (Storm 820; GE Healthcare) scanner and quan-
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tified with ImageQuant 5.2 software (GE Healthcare). The percentage of
uncleaved material was calculated from the ratio of uncleaved material to
starting material (SM).
Cell culture and virus. Huh7.5 cells were maintained in Dulbecco’s
modified minimal Eagle medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (3). A plasmid containing the
full-length HCV Jc1 cDNAwas cloned from chemically synthesized DNA
oligomers in collaboration with Ju-Tao Guo and Jinhong Chang (Baruch
S. Blumberg Institute, Doylestown, PA, USA). Infectious HCV Jc1 was
obtained by transcribing HCV Jc1 RNA in vitro using the Megascript kit
FIG 1 Geneticin’s effect on structure-dependent RNases cleaving HCV RNA nt 1 to 570. (A) (Top) Schematic representation of the secondary structure of nt 1
to 570 of HCVRNA open and closed forms and its processing products by RNase III and RNase P. RNase III and RNase P cleavage positions in each of the forms
are indicated by black and blue arrowheads, respectively. Highlighted in black is the minimal RNase P recognition site. miR-122 is represented in orange.
Long-range annealing sequences are colored red and green. The hypothetical position ofGeneticin binding at position 445 is indicated by a yellow spot. (Bottom)
Diagram of the sites of cleavage of HCVRNA by E. coliRNase III. Transcript (1–570) is represented by a line. RNase III cleavage sites in positions 27, 33, and 439,
respectively, are indicated by three arrowheads. Below are represented themain partial cleavage product bands, P1P2 andP2P3. In the presence ofmiR-122, a new
main cleavage site occurs at position 490, indicative of a different RNA conformation adopted by HCV RNA nt 1 to 570; its main partial products, P1-X and Y,
are represented below. (B and C) Determination of the effect of Geneticin on the structural recognition of HCV RNA by RNase III and RNase P ribozymes.
Autoradiograms of E. coliRNase III and Synechocystis sp. RNase P ribozyme cleavage of internally labeled RNAwith [-32P]GTP (32PRNA) transcriptsmigrated
in 4% polyacrylamide gels for panels B and C. Standard 0.001-U/l RNase III (B) and RNase P (C) ribozyme reactions were performed on HCV RNA in the
absence (lanes 3) of drug or in the presence of increasing concentrations of Geneticin base: 0.5, 5, 50, and 500g/ml (lanes 5 to 8) or identical concentrations of
Geneticin salt (lanes 10 to 13). Control incubations were done with no enzyme (lanes 2) and with no enzyme but with a Geneticin base (lanes 4 and 9). Lanes 1
were RNA maintained on ice. MW, molecular weight markers.
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(Ambion), followed by electroporation intoHuh7.5 cells and collection of
infectious viral particles from the cell culture (58). HCV RNA was tran-
scribed in vitrousing theMegascript kit (Ambion) and electroporated into
Huh7.5 cells (59). Generation of a virus stock and determination of virus
titers (50% tissue culture infective doses [TCID50] per milliliter) were
carried out as described in previous work (60). In general, infection of
Huh7.5 cells at a multiplicity of infection (MOI) of 0.015 for 4 days re-
sulted in virus yields of 0.5 104 to 0.5 105 TCID50/ml (61).
Immunofluorescence detection of HCV infection. Four days postin-
fection with HCV Jc1 (MOI 0.015), HCV Jc1-infected cells were fixed
with phosphate-buffered saline containing 1% paraformaldehyde and
then incubated for 20 min at 20°C with cold methanol. The cells were
then blocked and incubatedwithHCVNS3 primary antibody (cloneH23;
Abcam). Bound primary antibody was detected with Alexa Fluor 488-
conjugated goat anti-mouse IgG (Invitrogen) and visualized using a Zeiss
fluorescencemicroscope. The total number of foci was determined, as was
the number of stained cells in each focus.
RNA quantification of secreted HCV Jc1 by qRT-PCR. Four days
postinfection with HCV Jc1 (MOI 0.015), RNA in the culture medium
was extracted using TRIzol reagent (Invitrogen) and reverse transcribed
using SuperScript III (Invitrogen). Quantitative reverse transcription
(qRT)-PCR was performed using forward and reverse primers (5=-AGC
GTTGGGTTGCGAAAG-3= and 5=-CACTCGCAAGCGCCCT-3=, re-
spectively) and the probe 5=-6-carboxyfluorescein-CCTTGTGGTACTG
CCTGA-molecular-groove-binding nonfluorescent quencher-3= (Applied
Biosystems) in an Applied Biosystems 7500 thermal cycler. The standard
curve was generated using serial dilutions of in vitro-transcribed full-length
HCV Jc1 RNA.
Cell viability and Geneticin toxicity assays.Huh7.5 cells were plated
at a density of 1 103 to 2 103 cells/well on 96-well plates. Twenty-four
hours later, the cells were washed, and medium containing the required
concentration of Geneticin was added before incubating the cells for 4
days. Cell viability was then assessed using the resazurin (alamarBlue)
indicator dye. Dye conversion was quantitatively analyzed using a fluo-
rescent plate reader with excitation and emission at 550 and 580 nm,
respectively. Cell viability was expressed as a percentage of untreated cells.
RESULTS
Geneticin specifically inhibits RNase III cleavage of HCV
RNA1–570. Initial RNase III and RNase P cleavage experiments
involved a 570-base HCVRNA transcript in the closed conforma-
tion. The cleavage products of these two reactions have been char-
acterized (32, 33). Figure 1A shows a schematic representation of
the nt 1 to 570 RNA fragment that reveals the final reaction prod-
ucts (P1, P2, and P3) and the partial digestion products (P2P3 and
P1P2) as characterized for RNase III, located according to their
corresponding positions. The RNase P ribozyme cleavage site is
also shown. The autoradiograms in lanes 3 of Fig. 1B and C rep-
resent RNase III andRNase P ribozyme cleavage reactions, respec-
tively, while the products are identified on the right of the gels.
These initial experiments consisted of incubating the same
amount of HCV RNA1–570 with concentrations of Geneticin base
or its sulfate salt increasing from 0.5 to 500 g/ml in order to
inhibit HCVRNA cleavage by RNase III (0.0005U/l) or RNase P
ribozyme (67.5 nM). These inhibition reactions were performed
in the linear range for conversion of HCV RNA1–570 into its prod-
ucts. While cleavage by RNase P ribozyme was insensitive to both
forms of the drug, the quantities of nt 1 to 570 RNase III cleavage
products decreased when both forms of the drug were used at a
concentration of 500 g/ml (Fig. 1, lanes 8 and 13).
Conformational effect ofGeneticin onRNase III cleavage in-
hibition of HCV RNA1–570. We subsequently tested the effect of
Geneticin on HCV RNA1–570 in the presence of miR-122, which
switches the RNA from a closed to an open conformation, and in
the presence of a truncated nt 44 to 570 RNA fragment. The ab-
sence of the first 44 nt in the truncated fragment prevents the
formation of the closed conformation. Similar reactions were per-
formed on standard specificity-controlled substrates of RNase III
known as R1.1 (32, 62) and dsRNA from the yeast L-A virus ge-
nome.
Inhibition of HCV RNA1–570 processing at higher RNase III
activity. In contrast to the experiment illustrated in Fig. 1B, an
increased concentration of RNase III was tested to observe, not
only the effect of Geneticin on the main HCV RNA partial cleav-
age products, P1P2 and P2P3, but also the effect on how they are
subsequently processed to end products. This is significant, be-
cause we previously demonstrated that after the first cleavage,
which releases P1 and the partial product P2P3, the latter switches
its conformation from a closed to an open form, thus providing
the opportunity for a new cleavage in HCV RNA stem-loop VI, at
position 490, giving rise to the band product known as X. Figure
2A, left, shows that an increase in P2P3 formation was correlated
with a decrease in production of its X product.
Figure 2A reveals that when the substrate, or the SM, entered
the reaction in the C form, some substrate remained uncleaved
after being reacted with between 50 and 500 g/ml drug; this was
similar to the amount of drug needed to observe substrate accu-
mulation when the reaction was performed at a lower RNase III
FIG 2 Geneticin inhibits RNase III cleavage ofHCVRNAnt 1 to 570 in both the open and closed conformations. (A) Autoradiogramof E. coliRNase III cleavage
of internally labeledHCVRNAnt 1 to 570 in the absence (lanes 2 to 6) or presence (lanes 8 to 12) of 15 nMmiR-122. Lanes 1 and 7 represent the transcript alone
incubated on ice; lanes 2 and 8 represent transcript incubated in buffer and RNase III cleavage at 0.005 U/l. This standard RNase III reaction, using a constant
concentration of HCV RNA, was performed in the presence of increasing concentrations of Geneticin salt: 0.5, 5, 50, and 500 g/ml (lanes 3 to 6 and 9 to 12).
MW, molecular weight markers. The starting material and reaction products are indicated on the left. (B) Same as panel A with the HCV RNA nt 44 to 570
fragment.
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activity. This indicates that cleavage inhibition is independent of
RNase III activity and implies there is a direct interaction between
the drug and the substrate. When starting with the substrate par-
tially complexed with miR-122, which is predominantly in the O
form, a lower concentration was required to leave some intact
substrate: a range of 5 to 50 g/ml instead of 50 to 500 g/ml was
required, which implies that the O form is more sensitive to the
drug than the C form. In both cases, there is a direct inverse rela-
tionship between the amount of drug used and the amount of
substrate remaining after cleavage reactions on both RNA forms,
although it should be pointed out that this is not a dose-response
assay because the cleavage reaction is saturated. An analysis of the
effect of the drug on the cleavage pattern showed similarity be-
tween the two situations—the preferential accumulation of the
partial product P2P3.
We subsequently tested the HCV RNA nt 44 to 570 fragment
(which adopts only the open conformation [33]) in either the
presence or absence ofmiR-122 (Fig. 2B). Its single cleavage at site
490 produces the product X. In the presence of increasing concen-
trations of Geneticin, cleavage was inhibited in either the presence
or absence ofmiR-122 (Fig. 2B). This result implies that RNase III
cleavage of the open conformation is inhibited by the drug.
In order to fully eliminate the possibility that the drug inhibits
the enzyme, the effect of Geneticin was tested on the standard
substrate R1.1 RNA. The cleavage scheme is shown in Fig. 3B. No
inhibition was observed under any of the conditions employed
(Fig. 3A); in contrast, subtle cleavage stimulation was observed at
the highest drug concentration, a phenomenon that manifested
repeatedly. As an additional control, we tested the cleavage of 0.2
g of perfect dsRNA (obtained from the yeast virus L-A, which
has a double-stranded genome) using 0.002 and 0.01 U/ml of
RNase III (Fig. 3C). The result ranged from partial cleavage to
complete cleavage, independent of the presence of 0.5 to 500
g/ml of the drug (Fig. 3C).
Kinetic analysis of the cleavage inhibition mechanism. The
RNase III kinetic cleavage patterns for experiments in the presence
or absence of the drug and in the presence or absence of miR-122
are shown by the gels in Fig. 4A and B. The results from these gels
are summarized in the graphs in Fig. 4A and B as the percent
formation of cleavage products P2P3, X (in the absence of miR-
122), and also P1X (in the presence of miR-122) as a function of
time. HCV RNA1–570 alone, i.e., incubated in the absence of Ge-
neticin, displayed the characteristic kinetic cleavage pattern ob-
tained previously (Fig. 3B) (33); however, in the presence of the
drug, reduced RNase III cleavage was observed (Fig. 4A). Cleavage
inhibition was notable in the 10-min SM¡P2P3 and P1P2 reac-
FIG3 Geneticin does not inhibit RNase III processing of a natural and a standardRNA. (A) Autoradiogramof E. coliRNase III cleavage of control RNA substrate
T7 R1.1 mRNA, with the exception that the RNase III concentration was 0.001 U/l. (B) Schematic representation of the secondary structure of the R1.1
substrate. The primary RNase III cleavage site adjacent to T7 1.1mRNA is called the “R4 site.” The primary site is well known (depicted in reference 69). Primary
cleavage occurs between a U and a G residue of a stem-loop about 20 bp long, with an unpaired “bubble” region in themiddle, on the 3= side of the bubble (large
arrow). A secondary cleavage also occurs (62) (small arrow). The primary cleavage always occurs; when the secondary cleavage occurs, it takes place in the larger
product of the primary cleavage, yielding two new products. (C) (Left) RNase III activity was calibrated, using a substrate comprising 100 ng per 10l of dsRNA
of L-A virus extracted from yeast under conditions described previously (70). The cleavage reaction products were run in a 1% agarose gel stained with ethidium.
Lane 1, RNAmaintained in ice; lane 2, RNA incubated in buffer; lanes 3 to 6, RNA incubated with RNase III activity at 2 103, 5 103, 1 102, and 1 101
U/l, respectively. (Middle) A reaction similar to that for the left gel was performed. Lane 1, L-A virus RNA incubated in buffer; lane 2, L-A virus RNA incubated
with RNase III at 0.01 U/l; lanes 3 to 5, L-A virus RNA in the presence of increasing concentrations of Geneticin (5, 50, and 500 g/ml). (Right) Same as the
middle gel, with RNase III activity of 0.002 U/l. MW, molecular weight markers corresponding to a log2 ladder (NEB).
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FIG 4 Kinetic analysis of E. coli RNase III cleavage of HCV RNA in the presence or absence of miR-122 and Geneticin. (A) Autoradiogram of RNase III cleavage
of internally labeled HCV RNA nt 1 to 570 transcript in the absence () or presence () of Geneticin. (B) Same as panel A, but in the presence of a synthetic
miR-122. Lanes 1 to 7, 0, 10, 20, 30, 40, 50, and 60 min of incubation with RNase III at 0.005 U/l, respectively. Below each gel is a graphic representation of the
time course of processing of SM and main-product generation.
Ariza-Mateos et al.
930 aac.asm.org February 2016 Volume 60 Number 2Antimicrobial Agents and Chemotherapy
tion but was particularly marked in the processing of P2P3¡X
(either at 10min or at the end of the reaction). Notice that while in
the absence of Geneticin P2P3 and P1P2 were processed nearly to
completion, yielding X and P2 products, in its presence P2P3 was
retained as the major partial product in the gel and X was consis-
tently the product with the least production. Drug inhibition ki-
netics had a quantitatively similar effect on the reactions carried
out in the presence of miR-122 (Fig. 4B). The least represented
products in the presence of Geneticin were X and P1X. The low
proportions ofX andP1X can be directly associatedwith the direct
inhibition of cleavage at position 490, as observed for the RNA nt
44 to 570 fragment in Fig. 3B.
A very interesting point arises from the cleavage kinetics; in the
absence of miR-122 (Fig. 4A), most of the P2P3 produced is al-
ready present at the first time point regardless of Geneticin’s pres-
ence or absence; then, after this point and during the reaction
course, while in the absence of the drug SM continues its process-
ing into P2P3, in the presence of the drug, this step is blocked. This
suggests that in the presence of the drug the SM enters into the
reaction in two different conformations: closed, which was ex-
pected for HCV RNA1–570 and can quickly be processed to P2P3,
and open, which cannot be processed. In turn, this indicates that
the drug favors RNA switching to the O conformation in the ab-
sence of miR-122. Addition of miR-122 to the reaction mixture
did not have a significant effect on the kinetic profiles of the SM
and P2P3, based on miR-122 function, except that even less P2P3
was produced by the first time point; thus,miR-122 andGeneticin
combined their effects and promoted switching to the open con-
formation.
Inhibition of HCV replication in cell culture. To investigate
the antiviral effect of Geneticin on HCV replication and viral
spread, we first tested Geneticin activity on the initial spread of
infection and the formation of HCV Jc1 NS3-positive foci on a
monolayer of Huh7.5 cells. The spread of HCV infection in
Huh7.5 cells was clearly evident, with well-defined HCV NS3-
positive focus formation (Fig. 5A). Significantly, Geneticin di-
minished viral infection and spread from cell to cell with a 50%
effective concentration (EC50) of about 2 g/ml (Fig. 5C and
D). Accordingly, the HCV RNA yield in the culture medium
was reduced by 10-fold at 12.5 g/ml and by more than 100-
fold at 25 g/ml (Fig. 5D). Alpha interferon (IFN-) was used
as a positive control, with an EC50 of about 10 IU/ml (data not
shown). Importantly, the toxicity (50% lethal dose [LD50]) of
Geneticin in Huh7.5 cells was estimated to be about 530 g/ml
FIG5 Geneticin inhibits the spread ofHCV Jc1 infection inHuh7.5 cells. (A) (Top) Representative visualization ofHCVNS3 protein inHuh7.5 cells after 4 days
of infection in the presence or absence of 12.5 g/ml Geneticin. (Bottom) The background cell density was visualized using DAPI (4=,6-diamidino-2-phenylin-
dole). (B) Cell viability in the presence of Geneticin. (C) NS3-stained cells in each focus were counted and quantified for spread of viral infection in the absence
and presence of different concentrations of Geneticin. The values represent average results obtained from three independent experiments with EC50s of 	2
g/ml. (D) Virus yields in culture media as detected by qRT-PCR of culture medium at 96 h postinfection and then normalized to a percentage of the infected
control (EC50s,	12 g/ml). The values represent averages and standard deviations of results from three independent experiments. The toxicity of Geneticin in
Huh7.5 cells was detected using the alamarBlue assay (see Materials and Methods) (LD50,	530 g/ml).
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(Fig. 5B), suggesting that the selectivity index (LD50/EC50 ra-
tio) was about 265, implying selective anti-HCV activity of
Geneticin.
DISCUSSION
The aminoglycoside Geneticin, known for some time to interact
with the 16S rRNA of the E. coli ribosome, was applied to RNase P
and RNase III cleavage reactions in theHCVRNA1–570 region.We
observed thatwhile theRNase P ribozyme from Synechocystis sp. is
completely insensitive to the drug, it can selectively inhibit RNase
III cleavage in vitro.
Targeting of small-molecule RNAs has received considerable
interest since the discovery that specific interactions between low-
molecular-weightmetabolites andmRNAs formpart of themech-
anism controlling the appropriate biological functions of the RNA
molecules. These specific interactions are known as riboswitches
(63). While there are several screening methods for detection of
aminoglycosides binding to RNA (64), our evaluation does not
represent a direct analysis of the drug binding to the RNA mole-
cule. Our assay relies on the analysis of the specific structure-
dependent relationship of the RNase III-HCV RNA interaction in
the presence or absence of the drug. Important factors in assay
development included the components involved in the reaction:
the drug, the quality of the RNA substrate, the nature of the reac-
tion, and its control. Two forms of the drug, a sulfate salt and a
base, were tested in the first experiment and gave similar results,
suggesting that the specific structure of Geneticin was responsible
for the HCV RNA interaction and that sulfate salt did not influ-
ence it. The double-stranded character of the HCV regions being
tested in the RNase III cleavage assay might be very sensitive to
competition from dsRNA chains generated artifactually during
the T7-directed in vitro transcription process of the radiolabeled
RNA substrate (65). To avoid this, we subjected the transcribed
RNA to fractionation on a cellulose phosphate column, capable of
separating ssRNA from dsRNA, followed by denaturing electro-
phoresis, as described in Materials and Methods. The RNase III
used was a commercial preparation from a recombinant source
that we had previously characterized and validated for its specific-
ity versus authenticE. coliRNase III onT7R1.1mRNA, in order to
define the HCV cleavages as secondary (32). Therefore, we used
exactly the same reaction conditions in the present study.
We have previously demonstrated that two widely separated
sequence elements (proximal and distal regions) are simultane-
ously involved in the LRAmotif, while one or the other is cleaved
(32). Cleavage at the LRAwas also shown to favor transition of the
distal LRA strand to form stem-loop VI, where a new RNase III
cleavage occurs (33).
At first glance, the fact that cleavage at either the LRA motif in
the C conformation (closed) or stem-loop VI in starting material
(SM) plus miR-122 (open conformation) was inhibited seems to
indicate that the Geneticin-HCV RNA interaction favors a com-
mon conformation that cannot be processed by the enzyme. This
is supported by kinetic experiments indicating that either the sub-
strate or the larger partial product P2P3 switched to the O form in
the presence of the drug. Further processing of the open form to
either SM or P2P3 is then inhibited by the drug, as demonstrated
by the experiments with the nt 44 to 570 fragment, which is com-
pletely open (33), and by the inhibition of P2P3 processing into X.
The observation that a lower concentration of drug was required
to observe the same effect in the case of SM plus miR-122 than in
SM alone also agrees with the inhibition process. In summary, our
proposal for the inhibitionmechanism is that the drug pays part of
the energy cost associated with the transition from the closed to
the open conformation, while at the same time, the presence of the
drug inhibits RNase III cleavage in the stem-loop VI structure
(Fig. 6A).
This mode of action is similar to the mechanism proposed for
aminoglycoside-mediated inhibition of the aminoacylation reac-
tion of yeast tRNAAsp (13, 66). The key structure in the ribosomal
A site believed to accommodate the aminoglycosides is a dsRNA
motif that includes an A · A mismatch adjacent to a bulging ade-
nine (67); interestingly, a similar structure is clearly evident in
stem-loop VI (Fig. 6B), positions A445 and A492, very close to
RNase III cleavage at position G490.
An alternative hypothesis that cannot be ruled out is that there
may be a third stable structure acting as an intermediate in the
transition from LRA to stem-loop VI. In fact, experimental evi-
dence for annealing between sequences 372ACCAAAACG379 and
FIG 6 Model of cleavage inhibition and a potential drug binding site. We previously determined that the closed form is cleaved to give band products P2P3
(violet) and P1P2 (gray) (32, 33). Subsequently, each of these products follows a different RNase III processing route. The RNA fragment corresponding to P2P3
switches to an open form of the RNA, forming the stem of domain VI, which is then cleaved to give product band X (pink) (33) (the scheme is shown in Fig. 1A).
On the other hand, the P1P2 fragment, still in the closed form, is further processed to provide the P2 (red) fragment. In the presence of miR-122, the fraction of
RNA in the open form is cleaved directly to P1X. Other fragments shown are P1 in green and P3 in blue.
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431CGUUGGU437was gathered using single- and double-stranded
RNases (33). However, the annealing products were not structur-
ally characterized in further detail, and their possible role as inter-
mediate forms between the twomajor forms of the IRES, LRA and
stem-loop VI, was not determined.
The high concentration of drug needed to observe the in vitro
results deserves further consideration. The commercial RNase III
used in this study derives from a recombinant protein that has a
focus on dsRNA cleavage, rather than processing a long ssRNA
with a few specific sites for cleavage, which is the particular case in
HCV RNA. This is open to the possibility of contamination by
traces of conventional RNases, which can cleave ssRNA, or the
possibility that the recombinant enzyme acquires a subtly broad-
ened specificity (32). To avoid these potential problems, some of
whichmay differ between different RNase III batches, we included
a large quantity of highly purified yeast tRNA (58 M) in our
RNase III reactions, which served to protect our RNA from unde-
sired activities accompanying RNase III (32). We described the
reaction conditions previously (32), and in this study, we refer to
them as standard conditions. The conditions associated with our
study are that tRNAbinds aminoglycosides fromdifferent families
and with an affinity of	100 to 200M (68). Thus, in vitro RNase
III reactionswere performed at anHCVRNA/tRNAmolar ratio of
6  104 M HCV RNA/58 M yeast tRNA; this implies that
drug inhibition is restricted to strong RNA binders, which are
clearly able to compete with this high concentration of tRNA.
Detecting specific RNA structure-dependent cleavage inhibi-
tion by the drug not only provides an opportunity to interact
specifically and alter the IRES structure between the two confor-
mations (closed and open), which can help when studying the
multifunctionality of this part of the viral genome, but it also gives
us a potential therapeutic target that can eventually be studied to
determine HCV’s ability to undergo selective inhibition when
grown in a cell. Since Geneticin, unlike all other aminoglycosides,
is readily taken in by cells, we tested the effect of the compound on
viral growth inside cells.
In the present study, we demonstrated that Geneticin selec-
tively inhibits HCV Jc1 proliferation in Huh7.5 cells, as well as the
expression of the HCV NS3 protein (with an EC50 of about 2
g/ml). This is also consistent with Geneticin’s capacity to dra-
matically block the release of HCV genomic RNA and the spread
of viral infection. Geneticin-dependent inhibition of HCV Jc1
NS3-positive plaque formation decreased both plaque number
and size, demonstrating inhibition of both replication and viral
spread. The selectivity index (50% cytotoxic concentration
[CC50]/EC50) ofGeneticin’s anti-HCVactivity inHuh7.5 cells was
determined to be about 265, demonstrating that the mechanism
of Geneticin’s antiviral activity is selective and differs from its
toxic effects.
Geneticin’s antiviral molecular mechanism remains unclear.
To date, Geneticin has shown antiviral activity against different,
but not all, RNAviruses in a variety of cell lines (10, 11), suggesting
that the Geneticin-mediated antiviral mechanism does not de-
pend on the cell type. Therefore, the antiviral activity of Geneticin
is probably virus specific. In this study, we have shown that Gene-
ticin can interact directly with the RNA switch motif in HCV
RNA, supporting the idea that using aminoglycosides to target
conserved regions of viral RNAhas therapeutic potential. Further-
more, the interaction between Geneticin and the HCV RNA
switch provides the first concrete evidence that the RNA switch
within HCV RNA is important for the life cycle of HCV. There-
fore, further exploration of Geneticin virus selectivity and com-
parison of the antiviral mechanisms of different aminoglycosides
with respect to HCV are necessary.
The next phase of this work will involve experimental determi-
nation of the specific binding site for Geneticin using mutants
generated in vitro and by determining the resistance of these virus
mutants to the drug in vivo. Nevertheless, themain role of the drug
activity in vivo is a not a simple issue. The structures involved in
RNA switching, controlled by Geneticin, participate in several es-
sential viral functions. The 5=-proximal region flanking the IRES
has, quite convincingly, been observed to participate in transla-
tion inhibition, viral-RNA stabilization, andRNA replication. The
3= IRES flanking sequence is thought to participate in replication
and translation. Hence, when proximal and distal regions are
combined through switchable long-distance annealing, the role
associatedwith both of these regionsmight cover three areas of the
virus’ biology.
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